Diabetes Mellitus, Type 2 Clinical Trial
Official title:
Feasibility and Effectiveness of Electrochemical Dermal Conductance Measurement for the Screening of Diabetic Neuropathy in Primary Care.
Diabetes mellitus is the leading cause of polyneuropathy in the Western world. Diabetic neuropathy is a frequent complication of diabetes and may have great clinical transcendence due to pain and possible ulceration of the lower extremities. It is also a relevant cause of morbidity and mortality in patients with diabetes. Although the cause of polyneuropathy in patients with diabetes is only partially known, it has been associated with chronic hyperglycaemia suggesting the possible aetiopathogenic implication of advanced glycosylation end-products. The strategy of choice in the medical management of diabetic neuropathy is early detection since glycaemic control and the use of certain drugs may prevent or slow the development of this disease. Diabetic neuropathy most often presents with a dysfunction of unmyelinated C-fibers, manifested as an alteration of the sweat reflex of the eccrine glands. This dysfunction can now be demonstrated using a newly developed technology which measures dermal electrochemical conductivity. This noninvasive test is easy and cost-effective. The aim of the present study is to evaluate the feasibility and effectiveness of dermal electrochemical conductance measurement (quantitative expression of the sudomotor reflex) as a screening test for the diagnosis of diabetic neuropathy in patients in primary care.
The prevalence of diabetes mellitus (DM) is very high in Spain, being nearly 14% according to
oral glucose tolerance test (OGTT) results . The management of DM requires a significant
consumption of healthcare resources, mainly in relation to the care of vascular
complications. Among the late microvascular events which may develop in patients with DM,
polyneuropathy (PN) is the most common and disabling, and is the leading cause of morbidity
and mortality in these patients. Indeed, in Spain, the leading cause of neuropathy is DM,
with its prevalence increasing with the presence of DM and other risk factors such as
obesity.
PN is defined as the presence of symptoms and/or signs of peripheral nerve dysfunction in
people with DM after the exclusion of other possible causes. The Toronto Panel Consensus on
PN defined this disorder as "symmetrical, depending on large fibers, sensory-motor
attributable to metabolic and micro vessel disorders, as a result of chronic hyperglycemia
and other risk factors". In patients with PN, thin fibers (autonomic system - sweating) and
thermal and tactile sensitivity are first affected, followed by the involvement of large
fibers, presenting an altered vibrating sensation which eventually alters electromyography
(EMG) patterns. Therefore, dysfunction of sweat reflex in small distal fibers is one of the
earliest changes to be detected in these patients.
The most common clinical presentation of PN is distal symmetric polyneuropathy (DSPN), being
predominantly sensory in 80% of cases. Pain is the most important symptom, being described as
burning or flashing, lancinating, deep, and with frequent exacerbations during rest (4). Pain
often affects the quality of life of these patients, and it is a frequent cause of depression
and/or anxiety. Moreover, some patients may develop hypoesthesia, which may lead to severe
foot lesions.
The prevalence of DSPN varies greatly according to the population, definition and detection
method. The Rochester study, including more than 64,000 patients, reported the prevalence of
PN to be between 66% and 59% for type1 DM and type 2 DM, respectively. The 3rd report of the
Technical Study Group of Diabetes of the World Health Organization (WHO) described a
prevalence of 40% (8), and 50% in patients with more than 25 years of DM evolution. Pirart et
al. reported a prevalence ranging from 25 to 48% (7,10-17), while in Spain, Cabezas-Cerrato
et al. published a figure of 24.1%. DSPN-related factors are: age, DM duration, metabolic
control, male gender, acute myocardial infarction, hyperlipidemia (especially
hypertriglyceridemia), smoking, and general cardiovascular risk factors . Puig et al. also
included urinary albumin excretion as a risk factor of presenting DSPN.
The diagnosis of DSPN is commonly made based on signs and symptoms and usually includes the
use of several questionnaires such as the Neuropathy Disability Score (NDS), the Neuropathy
Symptoms Score (NSS) and the Michigan Neuropathy Instrument (MNI). These questionnaires are
easy to perform and are reproducible, sensitive and adequate for use in a screening program.
Additionally, It was included a short scale (UENS - Utah Early Neuropathy Scale) to screen
early neuropathy . This sensitive, fast and practical test, has 5 items and their score
ranges from 0 to 42 points.
There are many confirmatory tests, including measurements of nerve conduction velocity (EMG)
and bio-thesiometry or skin biopsy. However, those most commonly used are the measurement of
altered sensations using a vibrating tuning fork with 128 Hz and/or pressure with
Semmes-Weinstein 5:07 monofilament. Monofilament testing (MFT) is widely accepted and
recommended by all scientific societies because of its validity, predictive risk, efficiency
and simplicity. Feng et al. reported that MFT has a sensitivity of 57-93%, a specificity of
75-100%, a positive predictive value of 36-94% and a negative predictive value of 84-100%
compared to the measurement of nerve velocity by EMG. Although electrophysiological measures
are more objective and reproducible, they are limited in that they only detect dysfunction
based on the presence of thicker and faster (myelinated) fibers and show their involvement
later. Consequently, EMG is a specific, albeit very insensitive, test.
Recently developed noninvasive techniques are more reproducible and reliable for the
detection of early dysfunction of small fibers. One of these new techniques involves the
measurement of dermal electrochemical conductance (DEC) or sudomotor dysfunction index and
has been evaluated by well-designed studies (Calvet, Dupin, Winiecki, Black, 2013; Casellini
2013; Devigili 2008; Peltier 2009) which support its use as a screening test .
Ramachandran et al studied the use of DEC to detect diabetes and other disorders of glucose
metabolism. In a study on the use of DEC Casellini et al (5) applied a PN test which showed a
low sensitivity of 78% and a specificity of 92% in diabetic patients without neuropathy
compared to other subjects with neuropathy and a control group. In this latter study,
correlation with clinical parameters showed adequate reproducibility of the results,
particularly in regard to the measurements of the feet . Several other studies also obtained
significantly lower DEC values on comparing diabetic patients and controls. In a study of
patients following a 12-month program of intense physical activity, Raisanen et al (23)
observed a greater improvement in DEC compared to weight, waist circumference or maximum
oxygen volume (VO2 max).
Therefore, taking into account the large number of methods used and the learning curve
required to correctly implement these techniques as well as the absence of consensus as to
which method is the most adequate to diagnose DSPN, the aim of this study is to validate the
usefulness of DEC measurement in the early diagnosis of DSPN compared with traditional
techniques in the Primary Care setting.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05666479 -
CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
|
||
Completed |
NCT05647083 -
The Effect of Massage on Diabetic Parameters
|
N/A | |
Active, not recruiting |
NCT05661799 -
Persistence of Physical Activity in People With Type 2 Diabetes Over Time.
|
N/A | |
Completed |
NCT03686722 -
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
|
Phase 1 | |
Completed |
NCT02836704 -
Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)
|
Phase 4 | |
Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT04562714 -
Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy
|
N/A | |
Completed |
NCT02009488 -
Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
Completed |
NCT05896319 -
Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2
|
N/A | |
Recruiting |
NCT05598203 -
Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes
|
N/A | |
Completed |
NCT05046873 -
A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People
|
Phase 1 | |
Terminated |
NCT04090242 -
Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes
|
N/A | |
Completed |
NCT04030091 -
Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus
|
Phase 4 | |
Completed |
NCT03604224 -
A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
|
||
Completed |
NCT03620357 -
Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)
|
N/A | |
Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
Completed |
NCT03620890 -
Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy
|
Phase 4 | |
Withdrawn |
NCT05473286 -
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
|
||
Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
Completed |
NCT04531631 -
Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes
|
Phase 2 |